Bioethics Blogs

FDA Voucher for Leishmaniasis Treatment: Can Both Patients and Companies Win?

Girl in a leishmaniasis clinic in Muzzaffarpur, India.  Image credit: Anita KHEMKA/DNDi

Bernard Pécoul and Manica Balasegaram discuss whether drug companies have taken advantage of flaws in the FDA Priority Review Voucher program. It sounded like a pure global health success story. A company develops a drug for one of the most neglected … Continue reading »

The post FDA Voucher for Leishmaniasis Treatment: Can Both Patients and Companies Win? appeared first on Speaking of Medicine.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.